---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-25-000099"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:31:39.108563+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LivaNova Q2 revenue $352.5M (+10.7%), raises FY25 adjusted EPS guidance to $3.70-$3.80

## Summary
- Revenue $352.5M, +10.7% reported, +10.3% organic; GAAP EPS $0.50, adjusted EPS $1.05.
- Raised FY25 guidance: revenue growth 8-9% constant-currency, adj. EPS $3.70-$3.80 (midpoint +$0.10).
- Adj. free cash flow $47.8M; FY25 raised to $140-160M.
- Initiated CMS reconsideration for VNS Therapy for treatment-resistant depression based on RECOVER study.
- Published 24-month CORE-VNS data showing VNS reduces generalized tonic-clonic seizures in DRE.

## SEC filing metadata
- accession: 0001639691-25-000099
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969125000099/0001639691-25-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969125000099/livn-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-25-000099
- JSON: https://secwatch.observer/filing/0001639691-25-000099.json
- Plain text: https://secwatch.observer/filing/0001639691-25-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.